This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors participating in the Postebogui study in Guinea. The median time of reverse-transcription polymerase chain reaction negativity was 46.4 days after symptom onset (95% confidence interval, 11-82.6). The results emphasize the importance of the World Health Organization recommendations for survivors' management.
The Ebola virus (EBOV) is one of the most deadly human pathogens. The 2013-2016 outbreak of Ebola virus disease (EVD) in West Africa totaled at least 28 616 confirmed, probable, and suspected cases, resulting in 11 310 deaths and leaving >17 000 survivors in the 3 most affected countries: Guinea, Sierra Leone, and Liberia [1] . Many survivors have faced sequelae [2] , and EBOV can persist in immunologically privileged sites such as the eyes and the testes [3] .
A summary of the most recent published reviews on EBOV persistence in semen is provided in Supplementary Table 1 . Among studies posterior to these reviews, EBOV RNA has been detected in semen by reverse-transcription polymerase chain reaction (RT-PCR) up to 565 days after discharge from a treatment center in Liberia [4] , and up to 531 days after onset of disease in Guinea [5] . Viral persistence in the semen of male survivors is associated with a risk of EBOV sexual transmission, and 3 such cases of sexual transmission have been documented: 1 in Liberia [6] 1 in Sierra Leone [7] , and 1 in Guinea [5] .
The World Health Organization (WHO) recommends that "male Ebola survivors should be offered semen testing at 3 months after onset of disease, and then, for those who test positive, every month thereafter until their semen tests negative for virus twice by RT-PCR, with at least an interval of 1 week between tests" [8] .
The Postebogui study is currently investigating the clinical, virological, and psychosocial consequences of EVD in Guinea [9] . One of the study objectives is to model the presence of EBOV RNA in the semen of male participants to help quantify the risk of sexual transmission.
METHODS
The Postebogui study includes Ebola survivors from 4 study centers in Conakry, Forécariah, Macenta, and Nzérékoré in Guinea. All patients provided written informed consent for the study. Follow-up visits were scheduled at inclusion and 1, 3, 6, 9, 12, 18, and 24 months after inclusion but unscheduled visits were possible upon patient request. Semen samples were collected from men ≥15 years of age at each visit. The study's window for inclusion was large, as there was no limit for the time period between patients' discharge from the Ebola Treatment Centers (ETCs) and their enrollment in the cohort.
Semen samples were tested by RT-PCR for the presence of EBOV RNA (method detailed previously [9] ). Participants who had at least 1 RT-PCR result (either positive or negative) were included in the analysis. The RT-PCR results are expressed as cycle threshold (Ct) values that are inversely proportional to viral load, with a Ct cutoff for positivity of ≤40.9. Because virus isolation is not possible in Guinea, only RT-PCR was performed.
A time-to-event analysis was performed to model the time to test negativity-that is, the period between symptoms onset and the time when EBOV was no longer detected in semen with RT-PCR techniques. Data were interval-censored, meaning that test negativity occurred between the last positive and first negative RT-PCR test. Men were assumed to be positive at symptom onset. Data were right-censored for patients with no negative test result after the last positive result. The few samples that gave discordant results depending on the PCR technique were considered positive.
Parametric survival models were adjusted to estimate the probability of positive RT-PCR result over time, using exponential, Weibull, Gompertz, log-logistic, log-normal, gamma, and inverse Gaussian distributions. The model with the highest likelihood, and consistent with the Turnbull nonparametric estimator, was used to estimate the median time to negativity as well as the probability of testing positive for EBOV in semen at 3, 6, 12, and 18 months after symptom onset. The 95% confidence intervals (CIs) were obtained by implementing a Markov chain Monte Carlo algorithm, with noninformative prior for the parameters.
The model for the time to test negativity was then used to estimate, with 95% CIs, the likely number of male (≥15 years of age) EVD survivors with EBOV-positive semen in Guinea as of 31 August 2016. The total number male survivors ≥15 years of age was estimated from records of daily discharges from ETCs in Guinea, corrected by 2 methods: the proportion of men ≥15 years of age included in the Postebogui study stratified on 6 periods, or the country-wide proportion of men ≥15 years of age obtained from the weekly report of the National Coordination against EVD on the number of survivors, assuming a constant proportion of men ≥15 years of age discharged from the ETCs over time.
Data for these analyses were extracted in July 2016. The analyses were performed using Stata and R.
RESULTS
Among the 315 men aged ≥15 years included in the study at the time of data extraction, 188 provided at least 1 semen sample, with a total of 409 samples. The semen samples of the survivor linked to the February 2016 resurgence were included. The median age was 29.6 years of age (min 15.8-max 73.3), and the median time period between symptoms onset and inclusion in the Postebogui study was 319 days (min 15-max 810). The mean number of samples analyzed per patient was 2.8 (min 1-max 6).
A total of 15 patients (8.1%) had a least 1 positive RT-PCR result. For 3 samples, 1 RT-PCR was negative while the second yielded a positive Ct value that was close to the threshold value. For patients who had at least 1 positive RT-PCR result, the mean delay from symptoms onset to first positive semen sample was 223.8 days (min 29-max 548). The mean delay from symptoms onset to the last positive semen sample was 231.5 days (min 29-max 551). One patient had 3 positive results, another patient had 2 positive results, and the others tested positive only once. Five patients had negative results followed by positive ones for which values were not close to the detection threshold. Additional results are given in Supplementary Tables 1 and 2 .
The parametric survival model assuming a gamma distribution was associated to the highest likelihood, and led to a survival curve similar to the Turnbull nonparametric approach (Figure 1 ). Using this model, the median time to test negativity was 46.4 days after onset of symptoms (95% CI, 11-82.6). The probability of remaining positive for EBOV RNA in semen (according to RT-PCR) at 3, 6, 12, and 18 months was, respectively, estimated at 31.6% (95% CI, 18.6%-46.0%), 13.5% (95% CI, 7.8%-21.0%), 2.9% (95% CI, 1.1%-5.7%), and 0.7% (95% CI, 0.1%-2.0%). Among the 1270 Guinean patients discharged from ETCs, 514 were estimated to be men ≥15 years old from the Postebogui study, and of these male survivors, the model predicted that 2 (95% CI, 0.4-5.8) men would test positive as of 31 August 2016. We estimated 419 male survivors ≥15 years of age using the report of the National Coordination Against EVD on 3 August 2016 and our model again predicted that 2 (95% CI, 0.4-5.1) men would still be positive as of 31 August 2016.
DISCUSSION
The low proportion of men whose semen tested positive at least once by RT-PCR (8.1%) is probably due to the large time window from discharge from an ETC to inclusion in the study. Indeed, the median delay between EVD symptom onset and the first semen sample analyzed was 1 year. As the proportion of survivors with viral persistence in semen decreases over time [10] , patients included long after discharge (up to 810 days) were less likely to show positive results.
The large window of inclusion and the small proportion of positive patients also explain the large CIs around our point estimates. Although these estimates lack precision, they nonetheless provide meaningful insight into the persistence of EBOV in the semen using reliable statistical methods, taking into account the interval-censored nature of the data. The median time to negativity was estimated as 46.4 days after symptom onset, and the probability of testing positive 3 months after symptom onset was estimated at 31.6%. Even if a positive RT-PCR result is not a proof of infectivity, especially when the virus is detected at low level, these results emphasize the importance of implementing the current WHO recommendations for survivors' care and management in the immediate period after discharge from an ETC, providing safe-sex counseling to survivors and their sexual partners, and testing semen regularly until confirmed negativity. It should be stressed that the implementation of these recommendations requires a lot of human resources and constitutes a high laboratory challenge for a country such as Guinea. However, given the dynamics of the outbreak in Guinea, our model predicted that a very low number of male survivors would have a positive EBOV RNA RT-PCR semen sample at the end of the period of reinforced surveillance on 31 August 2016. These predictions, while using a different methodological approach, are consistent with projections made at the population level at the end of 2015 [11] .
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